A071701 Genomically-Guided Treatment Trial in Brain Metastases

Build status - In Progress

Recruiting

18 years - 99 years

All

Phase N/A

3 participants needed

1 Location

Brief description of study

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Brain Metastases,Brain Tumor,Brain Metastases, Brain Tumor
Age: 18 years - 99 years
Gender: All

Male and Female 18 years of age and older Brain Tumor

Updated on 04 Aug 2024. Study ID: 849264

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center